PET/CT of cancer patients: Part 2, deformable registration imaging before and after chemotherapy for radiation treatment planning in head and neck cancer

American Journal of Roentgenology

Volumn 199, Issue 5, 2012, Pages 968-974

  Schoenfeld, Jonathan D ^a   Kovalchuk, Nataliya ^b   Subramaniam, Rathan M ^c,d   Truong, Minh Tam ^b,c  

^a HARVARD RADIATION ONCOLOGY PROGRAM   (United States)

^b BOSTON MEDICAL CENTER   (United States)

^c BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^d DEPARTMENT OF PATHOLOGY   (United States)

Author keywords

Deformable registration; Head and neck cancer; Induction chemotherapy; Intensity modulated radiation therapy; Radiation treatment planning

Indexed keywords

ANTINEOPLASTIC AGENT; FLUORODEOXYGLUCOSE F 18;

CANCER RADIOTHERAPY; COMPUTER ASSISTED TOMOGRAPHY; DEFORMABLE REGISTRATION IMAGING; HEAD AND NECK CANCER; HUMAN; IMAGE PROCESSING; IMAGE QUALITY; INDUCTION CHEMOTHERAPY; INTENSITY MODULATED RADIATION THERAPY; MINIMAL RESIDUAL DISEASE; PATIENT POSITIONING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; TREATMENT PLANNING; TREATMENT RESPONSE; TUMOR LOCALIZATION; TUMOR VOLUME;

ALGORITHMS; FEMALE; FLUORODEOXYGLUCOSE F18; HEAD AND NECK NEOPLASMS; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY AND COMPUTED TOMOGRAPHY; PRACTICE GUIDELINES AS TOPIC; RADIOPHARMACEUTICALS; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; RADIOTHERAPY, INTENSITY-MODULATED;

EID: 84868032349     PISSN: 0361803X     EISSN: 15463141     Source Type: Journal    
DOI: 10.2214/AJR.12.8562     Document Type: Review

References (33)

1. Haddad RI, Shin DM. Recent advances in head and neck cancer. N Engl J Med 2008;359:1143-1154
2. Mendenhall WM, Amdur RJ, Palta JR. Intensitymodulated radiotherapy in the standard management of head and neck cancer: promises and pitfalls. J Clin Oncol 2006;24:2618-2623 (Pubitemid 46622082)
3. Kam MK, Leung SF, Zee B, et al. Prospective randomized study of intensity-modulated radiotherapy on salivary gland function in early-stage nasopharyngeal carcinoma patients. J Clin Oncol 2007;25:4873-4879 (Pubitemid 350220416)
4. Lee NY, De Arruda FF, Puri DR, et al. A comparison of intensity-modulated radiation therapy and concomitant boost radiotherapy in the setting of concurrent chemotherapy for locally advanced oropharyngeal carcinoma. Int J Radiat Oncol Biol Phys 2006;66:966-974 (Pubitemid 44633520)
5. Staffurth J, Board RD. A review of the clinical evidence for intensity-modulated radiotherapy. Clin Oncol 2010;22:643-657
6. Eisbruch A, Marsh LH, Dawson LA, et al. Recurrences near base of skull after IMRT for headandneck cancer: implications for target delineation in high neck and for parotid gland sparing. Int J Radiat Oncol Biol Phys 2004;59:28-42 (Pubitemid 38501504)
7. Chen AM, Farwell DG, Luu Q, Donald PJ, Perks J, Purdy JA. Evaluation of the planning target volume in the treatment of head and neck cancer with intensity-modulated radiotherapy: what is the appropriate expansion margin in the setting of daily image guidance? Int J Radiat Oncol Biol Phys 2011;81:943-949
8. Den RB, Doemer A, Kubicek G, et al. Daily image guidance with cone-beam computed tomography for head-and-neck cancer intensity-modulated radiotherapy: a prospective study. Int J Radiat Oncol Biol Phys 2010;76:1353-1359
9. Suzuki M, Nishimura Y, Nakamatsu K, et al. Analysis of interfractional set-up errors and intrafractional organ motions during IMRT for head and neck tumors to define an appropriate planning target volume (PTV) - and planning organs at risk volume (PRV)-margins. Radiother Oncol 2006;78:283-290
10. Subramaniam RM, Truong M, Peller P, Sakai O, Mercier G. Fluorodeoxyglucose-positron-emission tomography imaging of head and neck squamous cell cancer. AJNR 2010;31:598-604
11. 18F-FDG PET with conventional imaging modalities (CT, MRI, US) in lymph node staging of head and neck cancer. Eur J Nucl Med 1998;25:1255-1260 (Pubitemid 28446051)
12. Kubicek GJ, Champ C, Fogh S, et al. FDG-PET staging and importance of lymph node SUV in head and neck cancer. Head Neck Oncol 2010;2:19
13. 18F]fluorodeoxyglucose positron emission tomography and computed tomography and magnetic resonance imaging in oral cavity squamous cell carcinoma with palpably negative neck. J Clin Oncol 2006;24:4371-4376 (Pubitemid 46646246)
14. 18F-fluorodeoxyglucose/positron emission tomography and positron emission tomography/computed tomography imaging of squamous head and neck cancers. Semin Nucl Med 2005;35:214-219 (Pubitemid 41253360)
15. 18F]fluorodeoxyglucose (FDGPET) in the clinically negative neck: is it likely to be superior? Eur Arch Otorhinolaryngol 2004;261:479-483 (Pubitemid 39506424)
16. Schwartz DL, Ford E, Rajendran J, et al. FDGPET/CT imaging for preradiotherapy staging of head-and-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys 2005;61:129-136 (Pubitemid 40039114)
17. 18FDG-PET/CT as a predictive biomarker of outcome in patients with head and neck nonsquamous cell carcinoma. AJR 2011;197:976-980
18. Posner M. Evolving strategies for combined-modality therapy for locally advanced head and neck cancer. Oncologist 2007;12:967-974 (Pubitemid 47359139)
19. Vokes EE. Induction chemotherapy for head and neck cancer: recent data. Oncologist 2010;15(suppl 3):3-7
20. Hwang AB, Bacharach SL, Yom SS, et al. Can positron emission tomography (PET) or PET/computed tomography (CT) acquired in a nontreatment position be accurately registered to a head-and-neck radiotherapy planning CT? Int J Radiat Oncol Biol Phys 2009;73:578-584
21. Qazi AA, Pekar V, Kim J, Xie J, Breen SL, Jaffray DA. Auto-segmentation of normal and target structures in head and neck CT images: a featuredriven model-based approach. Med Phys 2011;38:6160-6170
22. Schwartz DL, Garden AS, Thomas J, et al. Adaptive radiotherapy for head-and-neck cancer: initial clinical outcomes from a prospective trial. Int J Radiat Oncol Biol Phys 2012;83:986-993
23. Shakam A, Scrimger R, Liu D, et al. Dose-volume analysis of locoregional recurrences in head and neck IMRT, as determined by deformable registration: a prospective multi-institutional trial. Radiother Oncol 2011;99:101-107
24. Piper J. Evaluation of an intensity-based freeform deformable registration algorithm. (abstract) Med Phys 2007;34:2353-2354
25. Kaus MR, Brock KK. Deformable image registration for radiation therapy planning: algorithms and applications. In: Leondes CT, ed. Biomechanical systems technology. Hackensack, NJ: World Scientific Publishing, 2007
26. Kessler ML. Image registration and data fusion in radiation therapy. Br J Radiol 2006;79(spec no 1):S99-S108 (Pubitemid 44614407)
27. International Commission on Radiation Units and Measurements. Prescribing, recording and reporting photon beam therapy, issue 62(supplement to ICRU report 50). Bethesda, MD: International Commission on Radiation Units and Measurements, 1999
28. Salama JK, Haddad RI, Kies MS, et al. Clinical practice guidance for radiotherapy planning after induction chemotherapy in locoregionally advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys 2009;75:725-733
29. Ireland RH, Dyker KE, Barber DC, et al. Nonrigid image registration for head and neck cancer radiotherapy treatment planning with PET/CT. Int J Radiat Oncol Biol Phys 2007;68:952-957 (Pubitemid 46818751)
30. Truong MT, Kovalchuk N, Jalisi S, Subramaniam R. Deformable registration of preoperative PET/CT imaging in head and neck cancer (HNC) patients undergoing postoperative radiotherapy (PORT) (abstract LL-ROE4455). RSNA 2011. Oak Brook, IL: Radiological Society of North America, 2011
31. Kudrimoti MR, Warren GW, Valentino J, et al. Results of reduction of treatment intensity based on response to a novel induction therapy in stage III and IV head and neck cancer. J Clin Oncol 2006;24(suppl 18):5561
32. Cohen E. Randomized study in locally advanced squamous cell carcinoma of head and neck. ClinicalTrials.gov. Accessed October 23, 2011
33. National Cancer Institute (NCI). Paclitaxel, cisplatin, and cetuximab followed by cetuximab and intensitymodulated radiation therapy in treating patients with HPV-associated stage III or stage IV cancer of the oropharynx that can be removed by surgery. ClinicalTrials.gov. Accessed October 23, 2011